By Business Daily |
Jun 26, 2025
Abbott has announced it will release its financial results for the second quarter of 2025 on Thursday, July 17, before the market opens.
By Business Daily |
Jun 20, 2025
Abbott's Healthy Food Rx program has demonstrated promising results in helping people with diabetes improve their diets and overall health, according to research presented at the American Diabetes Association's 85th Scientific Sessions.
By Business Daily |
Jun 13, 2025
The board of directors of Abbott has announced a quarterly common dividend of 59 cents per share.
By Business Daily |
May 27, 2025
Abbott has announced that the U.S. Food and Drug Administration (FDA) has approved its Tendyne transcatheter mitral valve replacement (TMVR) system.
By Business Daily |
May 15, 2025
Abbott has announced findings from its REFLECT studies, which reveal that the use of FreeStyle Libre continuous glucose monitoring (CGM) technology is linked to a significant reduction in hospitalizations for heart complications among individuals...
By Business Daily |
May 7, 2025
Abbott and Real Madrid have announced the launch of the 'Abbott Dream Team,' a program aimed at identifying young soccer talent across the United States.
By Business Daily |
May 1, 2025
Abbott and MotoAmerica have announced a collaboration to implement a rapid blood test for evaluating concussions at motorcycle races.
By Business Daily |
Apr 29, 2025
Abbott has announced a groundbreaking collaboration with Epic to integrate data from its FreeStyle Libre continuous glucose monitoring (CGM) systems directly into Epic's electronic health record systems in the United States.
By Business Daily |
Apr 27, 2025
Abbott has announced significant developments in its AVEIR Conduction System Pacing (CSP) technology, which were presented during the Heart Rhythm Society's 46th annual meeting in San Diego and published in the Heart Rhythm Journal.
By Business Daily |
Apr 26, 2025
Abbott has announced the 12-month results of its Volt CE Mark Study, demonstrating the safety and efficacy of the Volt PFA System for patients receiving pulsed field ablation (PFA) therapy to treat atrial fibrillation (AFib).
By Business Daily |
Apr 2, 2025
Abbott introduced a new delivery system for its Proclaim DRG neurostimulation technology, which aims to streamline implantation procedures for electrodes targeting the dorsal root ganglion (DRG).
By Business Daily |
Mar 31, 2025
Abbott has released new data from its TRILUMINATE Pivotal trial, revealing that the TriClip system for transcatheter edge-to-edge repair (TEER) eases the severity of tricuspid regurgitation (TR) symptoms.
By Business Daily |
Mar 27, 2025
Abbott has announced it received CE Mark in Europe for the Volt Pulsed Field Ablation (PFA) System, intended for treating atrial fibrillation (AFib).
By Business Daily |
Mar 26, 2025
Abbott will release its financial results for the first quarter of 2025 on April 16, before the market opens.
By Business Daily |
Mar 24, 2025
Abbott has announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System.
By K. R. Nelson |
Feb 26, 2025
Shedd Aquarium and Abbott have announced a significant corporate donation, with Abbott and its philanthropic foundation, Abbott Fund, pledging $10 million.
